Skip to content

Mariann Oemisch

Department of Neuroscience, Yale School of Medicine, New Haven, United States.

2 papers in the library · publishing 2022-2024

Papers

Therapeutic doses of ketamine acutely attenuate the aversive effect of losses during decision-making.

eLife May 3, 2024 Mariann Oemisch, Hyojung Seo

Ketamine, a rapid-acting antidepressant, reduces how aversive negative outcomes feel without changing how gains are evaluated, motivation, or other learning processes. In rhesus macaques making token-based decisions, ketamine lowered the impact of losses when given intramuscularly or intranasally. This effect was separate from side effects like fixation errors, which could be countered by strong motivation. The acute reduction in negative event impact may lead to longer-term antidepressant effects by preventing the cumulative buildup of negative memories. The findings suggest that disrupting affective memory could pose challenges in treating depression and invite further study across different mood states and time scales.

Therapeutic doses of ketamine acutely attenuate the aversive effect of losses during decision-making

bioRxiv Preprint Server July 25, 2022 Mariann Oemisch, Hyojung Seo preprint

Ketamine reduces the unpleasantness of negative outcomes without changing how gains are evaluated, according to a computational analysis of rhesus macaques making token-based decisions. The drug's effect on aversion was separable from side effects like fixation errors, which could be overcome with strong motivation to avoid mistakes. The authors propose that ketamine's acute dampening of negative events' impact might produce longer-term antidepressant effects by reducing the cumulative burden of slowly decaying memories of those events. They note that disruption-resistant affective memory could pose challenges in treating depression and call for further research on ketamine's action across diverse mood states and time scales.